Cover Image
市場調查報告書

乾燥症(乾性皮膚):開發平台評估

Xerosis (Dry Skin) - Pipeline Review, H1 2014

出版商 Global Markets Direct 商品編碼 253675
出版日期 內容資訊 英文 30 Pages
訂單完成後即時交付
價格
Back to Top
乾燥症(乾性皮膚):開發平台評估 Xerosis (Dry Skin) - Pipeline Review, H1 2014
出版日期: 2014年04月28日 內容資訊: 英文 30 Pages
簡介

乾燥症是皮膚或黏膜異常乾燥,過度曝曬於陽光或大氣中的污染物質等環境因子會造成皮膚受損之風險系數。症狀有乾燥、發癢、脫屑化,尤其是手臂和腿部會有白色脫屑化,皮膚呈現發紅或粉紅的慘狀、甚至龜裂等,治療方法有利用皮膚軟化藥等。

本報告網羅全球乾燥症(乾性皮膚)治療藥開發平台資訊,提供目前開發平台狀況和最新趨勢,藥物簡介,再加上主要企業及開發中的商品評估等。

目錄

簡介

  • 分析範圍

乾燥症(乾性皮膚)概要

治療藥的開發

  • 乾燥症(乾性皮膚)開發中產品:概要
  • 乾燥症(乾性皮膚)開發中產品:比較分析

乾燥症(乾性皮膚):正在開發的治療藥:各企業

乾燥症(乾性皮膚):開發中產品概況

  • 後期階段的產品
  • 初期階段的產品

乾燥症(乾性皮膚):開發中的產品:各企業

乾燥症(乾性皮膚):治療藥的開發企業

  • Laboratoires Pierre Fabre SA
  • Evocutis PLC
  • Foamix Ltd.

乾燥症(乾性皮膚):治療藥的評估

  • 單劑治療藥
  • 組合產品
  • 各給藥途徑
  • 各類型分子

藥物簡介

  • V0034-CR01B
  • 皮膚軟化劑1
  • 尿素
  • (尿素 + 乳酸)
  • 皮膚軟化劑2
  • 皮膚軟化劑3
    • 產品概要
    • 作用機制
    • R&D的進展

暫停中的計劃

開發中止的產品

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC4907IDB

Global Markets Direct's, 'Xerosis (Dry Skin) - Pipeline Review, H1 2014', provides an overview of the Xerosis (Dry Skin)'s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Xerosis (Dry Skin), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Xerosis (Dry Skin) and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Xerosis (Dry Skin)
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Xerosis (Dry Skin) and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Xerosis (Dry Skin) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Xerosis (Dry Skin) pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Reasons to buy

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Xerosis (Dry Skin)
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Xerosis (Dry Skin) pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Xerosis (Dry Skin) Overview
  • Therapeutics Development
    • Pipeline Products for Xerosis (Dry Skin) - Overview
    • Pipeline Products for Xerosis (Dry Skin) - Comparative Analysis
  • Xerosis (Dry Skin) - Therapeutics under Development by Companies
  • Xerosis (Dry Skin) - Pipeline Products Glance
    • Late Stage Products
    • Early Stage Products
  • Xerosis (Dry Skin) - Products under Development by Companies
  • Xerosis (Dry Skin) - Companies Involved in Therapeutics Development
    • Laboratoires Pierre Fabre SA
    • Evocutis PLC
    • Foamix Ltd.
  • Xerosis (Dry Skin) - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Combination Products
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • V0034-CR01B - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Emollient-1 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Urea - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • (urea + lactic acid) - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Emollient-2 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Emollient-3 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Xerosis (Dry Skin) - Dormant Projects
  • Xerosis (Dry Skin) - Discontinued Products
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Xerosis (Dry Skin), H1 2014
  • Number of Products under Development for Xerosis (Dry Skin) - Comparative Analysis, H1 2014
  • Number of Products under Development by Companies, H1 2014
  • Comparative Analysis by Late Stage Development, H1 2014
  • Comparative Analysis by Early Stage Development, H1 2014
  • Products under Development by Companies, H1 2014
  • Xerosis (Dry Skin) - Pipeline by Laboratoires Pierre Fabre SA, H1 2014
  • Xerosis (Dry Skin) - Pipeline by Evocutis PLC, H1 2014
  • Xerosis (Dry Skin) - Pipeline by Foamix Ltd., H1 2014
  • Assessment by Monotherapy Products, H1 2014
  • Assessment by Combination Products, H1 2014
  • Number of Products by Stage and Route of Administration, H1 2014
  • Number of Products by Stage and Molecule Type, H1 2014
  • Xerosis (Dry Skin) - Dormant Projects, H1 2014
  • Xerosis (Dry Skin) - Discontinued Products, H1 2014

List of Figures

  • Number of Products under Development for Xerosis (Dry Skin), H1 2014
  • Number of Products under Development for Xerosis (Dry Skin) - Comparative Analysis, H1 2014
  • Number of Products under Development by Companies, H1 2014
  • Comparative Analysis by Early Stage Products, H1 2014
  • Assessment by Monotherapy Products, H1 2014
  • Number of Products by Top 10 Route of Administration, H1 2014
  • Number of Products by Stage and Top 10 Route of Administration, H1 2014
  • Number of Products by Stage and Top 10 Molecule Type, H1 2014
Back to Top